23andMe Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Employees
  • 660
Employees
  • Latest Deal Type
  • PIPE
  • (Announced)
  • Latest Deal Amount
  • $250M
Latest Deal Amount
  • Investors
  • 67

23andMe General Information

Description

Developer of consumer genetic research technology designed to help people access, understand and benefit from the human genome. The company's platform offers gene indexing while highlighting significant findings through web-based interactive tools, enabling patients to gain insights into personal ancestry, genealogy, and inherited traits.

Contact Information

Website
www.23andme.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Information Services (B2C)
Other Devices and Supplies
Primary Office
  • 223 North Mathilda Avenue
  • Sunnyvale, CA 94086
  • United States
+1 (800) 000-0000

23andMe Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

23andMe Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. PIPE 04-Feb-2021 $250M 00.000 Announced Generating Revenue
16. Reverse Merger 04-Feb-2021 00000 00000 00.00 Announced Generating Revenue
15. Later Stage VC (Series F) 01-Dec-2020 000.00 00000 00.000 Completed Generating Revenue
14. Secondary Transaction - Private 01-May-2019 00000 Completed Generating Revenue
13. Secondary Transaction - Private 01-Jan-2019 00000 Completed Generating Revenue
12. Secondary Transaction - Private 03-Dec-2018 00000 Completed Generating Revenue
11. Later Stage VC (Series F) 23-Jul-2018 00000 00000 00.000 Completed Generating Revenue
10. Secondary Transaction - Private 22-Dec-2017 00000 Completed Generating Revenue
9. Later Stage VC (Series F) 11-Sep-2017 $250M $491M 00.000 Completed Generating Revenue
8. Grant 13-Oct-2016 $1.7M $241M Completed Generating Revenue
To view 23andMe’s complete valuation and funding history, request access »

23andMe Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series F1 00,000,000 00.000000 00.00 000.00 000.00 00 000.00 00.00
Series F 00,000,000 00.000000 00.00 000.00 000.00 00 000.00 00.000
Series E 00,000,000 00.000000 00.00 000.00 000.00 00 000.00 0.000
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series C 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series B 9,048,560 $0.000010 $0.18 $3.07 $3.07 1x $3.07 5.54%
Series A 7,119,936 $0.000010 $0.08 $1.26 $1.26 1x $1.26 4.36%
To view 23andMe’s complete cap table history, request access »

23andMe Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of consumer genetic research technology designed to help people access, understand and benefit from the human
Laboratory Services (Healthcare)
Sunnyvale, CA
660 As of 2021
00.000
000000000 00.000

00000 00

minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Dui
0000000000000
Aliso Viejo, CA
000 As of 0000
00 0000-00-00
000000&0

00000000

nsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut eni
0000000000000
Hyderabad, India
00 As of 0000
00.000
00000 00000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

23andMe Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ambry Genetics Private Equity-Backed Aliso Viejo, CA 000 000000&0
00000000000 Private Equity-Backed Hyderabad, India 00 00.000 00000 00000 00.000
00 0000 0000000 Venture Capital-Backed Branford, CT 00 00.000 000000000 - 00.000
000000000 Venture Capital-Backed Foster City, CA 000 00000 000000 - 000 00000
0000000 0000000 Venture Capital-Backed Boston, MA 000 00000 00000000000 00000
You’re viewing 5 of 18 competitors. Get the full list »

23andMe Executive Team (39)

Name Title Board Seat Contact Info
Anne Wojcicki Chief Executive Officer & Co-Founder
Steve Schoch Chief Financial Officer
Kathy Hibbs JD Chief Legal & Regulatory Officer
Mike Polcari Vice President, Chief Architect, Software Architect and Director of Software Engineering
David Baker Chief Security Officer
You’re viewing 5 of 39 executive team members. Get the full list »

23andMe Board Members (7)

Name Representing Role Since
Neal Mohan 23andMe Board Member 000 0000
Patrick Chung JD Xf (Specialized Finance) Board Member 000 0000
Richard Scheller Ph.D Self Board Member 000 0000
Roelof Botha Sequoia Capital Board Member 000 0000
You’re viewing 4 of 7 board members. Get the full list »

23andMe Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

23andMe Investors (67)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Breyer Capital Venture Capital Minority 000 0000 000000 0
Fabrica Ventures Venture Capital Minority 000 0000 000000 0
Light Street Investments Venture Capital Minority 000 0000 000000 0
Polyvalent Capital Venture Capital Minority 000 0000 000000 0
Snow Fox Partners Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 67 investors. Get the full list »

23andMe Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 0000000000 21-Apr-2021 00000 00000 00 00.00 Decision/Risk Analysis
00 00000000000 04-Feb-2021 000000000000000000 Special Purpose Acquisition Company (SPAC) 0000 00000000
000000 00 000000 20-Jul-2015 00000 00000 00 0000 Other Healthcare Services 0000 00000000
CureTogether 10-Jul-2012 Merger/Acquisition Decision/Risk Analysis 0000 00000000
To view 23andMe’s complete investments and acquisitions history, request access »

23andMe Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00 000000 20-Jul-2015 00000 00000 00 0000 Completed
  • 14 buyers
To view 23andMe’s complete exits history, request access »